Member Info for RorkesDrift

The talk about antigenic sin is that the proteins on virus surface change but the body produces the original AB and cannot switch to new form. Therefore supplemental ABs (mabs) would presumably help. Would need to determine whether affimers were effective and safe but if so they offer a quicker and more flexible approach. Hopefully someone is doing this but given its Avacta ......

Agreed. Start stocking up on bog roll now

On plus side for the share (that doesn't sit well) a short lead time to accurate test would be a helpful time a govt trying to plan ahead. Make an affimer for each VoC as and when they appear. Document states we can predicted drift so need a solution to an ever changing enemy. That isn't ABs.

Homework

https://en.wikipedia.org/wiki/Original_antigenic_sin

The thing about affimers is they are not locked into original sin.

Seems Sage think reducing transmission is a pretty good thing to do - reduces antigenic shift in the face of selection pressure.

Oh hang on.....

PS Talk about stock piling therapeutics for when the inevitable happens. Covid stocks back to popular demand.

With thanks to gkb47

https://www.gov.uk/government/publications/long-term-evolution-of-sars-cov-2-26-july-2021

Yep - apologies for the Socratic reasoning

I agree with you

Ava006 First patient missed ?

Not worried but given it was a AS self imposed deadline again.....

Is he using the same time system?

So ODX are not making Avacta test.

Will UK govt only buy test that are made by ODX - implies ODX acting as the govt manufacturing division?

Are ODX able to set price of govt test -maybe, like others there costs and therefore Avactas were too high - see BBI

We is happy then - thank you for the alcon info - appreciated

And relax. .

mmmmmmm.......

May i ask if there is a safety monitoring committee. If so why would anyone do an interim - what would you do with the result.

They might try and get topline data out as soon as last patient hits primary endpoint - timing of that is key.

if other results come out they may try and get a blinded committee to examine data for futility. Seems to me there are a number of projects on-going. Drs talk to each other. Standby :-}

My misteak -Surescreen is 20million tests. Published price is £6.

Cannot see if detects delta.

Acon seem biggest threat -Anterior nasal, self test.

I can confirm that is correct.

im guessing avacta were pleased with their sensitivity result but were immediately concious that the error bars (the range of possible sensitivity) were large. presumably work would begin immediately on increasing the n number in order to reduce the error bar - 98% sensitivity with small error bar may be better than 99% with a large one. There again that would need a sense of urgency.

on a related note surescreen have won a contract for £20M. I think this is about 2-3 weeks stock but why this amount is unclear. It is politically astute and covers a certain Lords rs - boris visited the factory but maybe it is all they can make or is limited to allow multiple uk companies in. just a thought.

His lordship is speaking Latin

Its cause he is kow towing to a Centurion

This is motion towards. .

Bump

Self testing

What price?

Good point - they might even sell some

Must read but.....

SP didn't move - have similar multi shots on goal.

Market now waiting definitive news rather than warm feelings. However, Chinese tie up looks like affimers will be high profile over there